Please Wait.....
Report
Ocular Drug Delivery Market By Technology (Topical, Ocular Insert, Intraocular Implants, In-Situ Gel, Others), By Formulation Type (Solution, Emulsion, Suspension, Ointment, Others), By Disease Indication (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age related macular degeneration, Others), By End User (Hospitals, Ophthalmic Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-11-01 I 248 Pages I Allied Market Research
The ocular drug delivery market was valued for $67.7 billion in 2022 and is estimated to reach $115.5billion by 2032, exhibiting a CAGR of 5.5% from 2023 to 2032.The targeted delivery of pharmaceuticals and therapeutic agents to the eye is known as ocular drug delivery. This delivery system aims to treat different eye diseases and ailments by efficiently and effectively delivering medications to the targeted areas of the eye, such as the cornea, conjunctiva, or retina. This drug delivery system is essential to effectively treat illnesses like glaucoma, age-related macular degeneration, dry eye disease, and others. A variety of techniques are used in ocular drug delivery, such as eye drops, ointments, implants, inserts, and cutting-edge technologies including intravitreal injections and in-situ gels.
The ocular drug delivery market growth is driven by increase in the incidences of ocular diseases, rise in aging population, and surge in development of new technologies for ocular drug delivery. Surge in aging population and shift in lifestyles are the major risk factors that contribute to the increased prevalence of eye disorders such as glaucoma, age-related macular degeneration (AMD), and others. The risk of getting age-related macular degeneration rises with the aging population. For instance, according to National Center for Biotechnology Information (NCBI) 2022, about 200 million people are estimated to have AMD and by 2040, this number is expected to reach 300 million. Thus, there is an increase in need for efficient drug delivery systems that can offer consistent and focused delivery of drugs to treat these illnesses.
Furthermore, continuous technical advancements to improve ocular drug delivery strategies are also driving the market growth. These developments are intended to enhance the effectiveness, accuracy, and patient experience while administering drugs to the eyes. For instance, sustained-release intraocular implants, such as the ILUVIEN, which deliver fluocinolone acetonide and dexamethasone, respectively, have become recognized as ground-breaking technologies. These implants ensure stable drug levels in the eye and minimize the need for frequent eye drops by releasing medication gradually over an extended period of time.
In addition, increase in R&D activities and reduced side effects of drugs due to use of advanced drug delivery technologies boost the market growth. However, stringent regulatory guidelines for the drug approvals limit the growth of the ocular drug delivery market. Furthermore, high cost associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new ocular drug delivery formulation thereby impacting the market growth.Further, shift of patient preference towards the non-invasive treatments due to ease of administration and improved compliance also drives the demand for eye drops, eye ointments, and other formulations. For instance, according to National Centers for Biotechnology Information (NCBI), topical eye drop is the most convenient and highly preferred route of drug administration.
The ocular drug delivery market is segmented on the basis of technology, formulation type, disease indication, end user, and region. On the basis of technology, the market is classified into topical, ocular insert, intraocular implants, in-situ gels, and others. As per formulation type, the market is categorized into solution, emulsion, suspension, ointment, and others. On the basis of disease indication, the market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, age related macular degeneration, and others. On the basis of end use the market is divided into hospitals, ophthalmic clinics, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global ocular drug delivery market are Ocular Therapeutix, Inc., EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Santen Pharmaceutical Co., Ltd., Abbvie Inc., Novaliq GmbH, Bausch & Lomb, Alimera Sciences, Inc., Nicox, and Kiora Pharmaceuticals, Inc. Key players operating in the market have adopted product approval and collaboration as their key strategies to expand their market share and product portfolio.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ocular drug delivery market analysis from 2022 to 2032 to identify the prevailing ocular drug delivery market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the ocular drug delivery market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global ocular drug delivery market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Technology
- Topical
- Ocular Insert
- Intraocular Implants
- In-Situ Gel
- Others
By Formulation Type
- Ointment
- Others
- Solution
- Emulsion
- Suspension
By End User
- Others
- Hospitals
- Ophthalmic Clinics
By Disease Indication
- Glaucoma
- Diabetic Retinopathy
- Dry Eye Syndrome
- Age related macular degeneration
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Bausch Health Companies, Inc.
- Ocular Therapeutix, Inc.
- Clearside Biomedical, Inc.
- Alimera Sciences, Inc.
- EyePoint Pharmaceuticals, Inc.
- Kiora Pharmaceuticals, Inc.
- Nocox
- Santen Pharmaceutical Co., Ltd.
- Novaliq GmbH
- AbbVie Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Technological advancements in the ocular drug delivery
3.4.1.2. Surge in prevalence of eye disorders
3.4.1.3. Rise in geriatric population
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for product approvals
3.4.3. Opportunities
3.4.3.1. Surge in new product approvals and strong product pipeline
CHAPTER 4: OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Topical
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Ocular Insert
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Intraocular Implants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. In-Situ Gel
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Solution
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Emulsion
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Suspension
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Ointment
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Glaucoma
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diabetic Retinopathy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Dry Eye Syndrome
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Age related macular degeneration
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: OCULAR DRUG DELIVERY MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Ophthalmic Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: OCULAR DRUG DELIVERY MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Technology
8.2.3. Market size and forecast, by Formulation Type
8.2.4. Market size and forecast, by Disease Indication
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Technology
8.2.6.1.2. Market size and forecast, by Formulation Type
8.2.6.1.3. Market size and forecast, by Disease Indication
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Technology
8.2.6.2.2. Market size and forecast, by Formulation Type
8.2.6.2.3. Market size and forecast, by Disease Indication
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Technology
8.2.6.3.2. Market size and forecast, by Formulation Type
8.2.6.3.3. Market size and forecast, by Disease Indication
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Technology
8.3.3. Market size and forecast, by Formulation Type
8.3.4. Market size and forecast, by Disease Indication
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Technology
8.3.6.1.2. Market size and forecast, by Formulation Type
8.3.6.1.3. Market size and forecast, by Disease Indication
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Technology
8.3.6.2.2. Market size and forecast, by Formulation Type
8.3.6.2.3. Market size and forecast, by Disease Indication
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Technology
8.3.6.3.2. Market size and forecast, by Formulation Type
8.3.6.3.3. Market size and forecast, by Disease Indication
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Technology
8.3.6.4.2. Market size and forecast, by Formulation Type
8.3.6.4.3. Market size and forecast, by Disease Indication
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Technology
8.3.6.5.2. Market size and forecast, by Formulation Type
8.3.6.5.3. Market size and forecast, by Disease Indication
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Technology
8.3.6.6.2. Market size and forecast, by Formulation Type
8.3.6.6.3. Market size and forecast, by Disease Indication
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Technology
8.4.3. Market size and forecast, by Formulation Type
8.4.4. Market size and forecast, by Disease Indication
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Technology
8.4.6.1.2. Market size and forecast, by Formulation Type
8.4.6.1.3. Market size and forecast, by Disease Indication
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Technology
8.4.6.2.2. Market size and forecast, by Formulation Type
8.4.6.2.3. Market size and forecast, by Disease Indication
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Technology
8.4.6.3.2. Market size and forecast, by Formulation Type
8.4.6.3.3. Market size and forecast, by Disease Indication
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Technology
8.4.6.4.2. Market size and forecast, by Formulation Type
8.4.6.4.3. Market size and forecast, by Disease Indication
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Technology
8.4.6.5.2. Market size and forecast, by Formulation Type
8.4.6.5.3. Market size and forecast, by Disease Indication
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Technology
8.4.6.6.2. Market size and forecast, by Formulation Type
8.4.6.6.3. Market size and forecast, by Disease Indication
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Technology
8.5.3. Market size and forecast, by Formulation Type
8.5.4. Market size and forecast, by Disease Indication
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Technology
8.5.6.1.2. Market size and forecast, by Formulation Type
8.5.6.1.3. Market size and forecast, by Disease Indication
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Technology
8.5.6.2.2. Market size and forecast, by Formulation Type
8.5.6.2.3. Market size and forecast, by Disease Indication
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Technology
8.5.6.3.2. Market size and forecast, by Formulation Type
8.5.6.3.3. Market size and forecast, by Disease Indication
8.5.6.3.4. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Technology
8.5.6.4.2. Market size and forecast, by Formulation Type
8.5.6.4.3. Market size and forecast, by Disease Indication
8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. AbbVie Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Bausch Health Companies, Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Ocular Therapeutix, Inc.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. EyePoint Pharmaceuticals, Inc.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Clearside Biomedical, Inc.
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Key strategic moves and developments
10.6. Santen Pharmaceutical Co., Ltd.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Novaliq GmbH
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Alimera Sciences, Inc.
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Nocox
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Kiora Pharmaceuticals, Inc.
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
LIST OF TABLES
TABLE 01. GLOBAL OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 02. OCULAR DRUG DELIVERY MARKET FOR TOPICAL, BY REGION, 2022-2032 ($MILLION)
TABLE 03. OCULAR DRUG DELIVERY MARKET FOR OCULAR INSERT, BY REGION, 2022-2032 ($MILLION)
TABLE 04. OCULAR DRUG DELIVERY MARKET FOR INTRAOCULAR IMPLANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. OCULAR DRUG DELIVERY MARKET FOR IN-SITU GEL, BY REGION, 2022-2032 ($MILLION)
TABLE 06. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 08. OCULAR DRUG DELIVERY MARKET FOR SOLUTION, BY REGION, 2022-2032 ($MILLION)
TABLE 09. OCULAR DRUG DELIVERY MARKET FOR EMULSION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. OCULAR DRUG DELIVERY MARKET FOR SUSPENSION, BY REGION, 2022-2032 ($MILLION)
TABLE 11. OCULAR DRUG DELIVERY MARKET FOR OINTMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 12. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 14. OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 15. OCULAR DRUG DELIVERY MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. OCULAR DRUG DELIVERY MARKET FOR DRY EYE SYNDROME, BY REGION, 2022-2032 ($MILLION)
TABLE 17. OCULAR DRUG DELIVERY MARKET FOR AGE RELATED MACULAR DEGENERATION, BY REGION, 2022-2032 ($MILLION)
TABLE 18. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. GLOBAL OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. OCULAR DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. OCULAR DRUG DELIVERY MARKET FOR OPHTHALMIC CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 23. OCULAR DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. U.S. OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 30. U.S. OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 31. U.S. OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 32. U.S. OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. CANADA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 34. CANADA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 35. CANADA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 36. CANADA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. MEXICO OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 38. MEXICO OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 39. MEXICO OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 40. MEXICO OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. EUROPE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 42. EUROPE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 43. EUROPE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 44. EUROPE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. EUROPE OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 46. GERMANY OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 47. GERMANY OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 48. GERMANY OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 49. GERMANY OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. FRANCE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 51. FRANCE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 52. FRANCE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 53. FRANCE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. UK OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 55. UK OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 56. UK OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 57. UK OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. ITALY OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 59. ITALY OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 60. ITALY OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 61. ITALY OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. SPAIN OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 63. SPAIN OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 64. SPAIN OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 65. SPAIN OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. JAPAN OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 76. JAPAN OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 77. JAPAN OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 78. JAPAN OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. CHINA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 80. CHINA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 81. CHINA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 82. CHINA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. INDIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 84. INDIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 85. INDIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 86. INDIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 88. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 89. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 92. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 93. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 94. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 99. LAMEA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 100. LAMEA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 101. LAMEA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 102. LAMEA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. LAMEA OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 104. BRAZIL OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 105. BRAZIL OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 106. BRAZIL OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 107. BRAZIL OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 110. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 114. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 118. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 120. ABBVIE INC.: KEY EXECUTIVES
TABLE 121. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 122. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 123. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 124. ABBVIE INC.: KEY STRATERGIES
TABLE 125. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
TABLE 126. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
TABLE 127. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
TABLE 128. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
TABLE 129. OCULAR THERAPEUTIX, INC.: KEY EXECUTIVES
TABLE 130. OCULAR THERAPEUTIX, INC.: COMPANY SNAPSHOT
TABLE 131. OCULAR THERAPEUTIX, INC.: PRODUCT SEGMENTS
TABLE 132. OCULAR THERAPEUTIX, INC.: PRODUCT PORTFOLIO
TABLE 133. EYEPOINT PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 134. EYEPOINT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 135. EYEPOINT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 136. EYEPOINT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 137. CLEARSIDE BIOMEDICAL, INC.: KEY EXECUTIVES
TABLE 138. CLEARSIDE BIOMEDICAL, INC.: COMPANY SNAPSHOT
TABLE 139. CLEARSIDE BIOMEDICAL, INC.: PRODUCT SEGMENTS
TABLE 140. CLEARSIDE BIOMEDICAL, INC.: SERVICE SEGMENTS
TABLE 141. CLEARSIDE BIOMEDICAL, INC.: PRODUCT PORTFOLIO
TABLE 142. CLEARSIDE BIOMEDICAL, INC.: KEY STRATERGIES
TABLE 143. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 144. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 145. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 146. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 147. NOVALIQ GMBH: KEY EXECUTIVES
TABLE 148. NOVALIQ GMBH: COMPANY SNAPSHOT
TABLE 149. NOVALIQ GMBH: PRODUCT SEGMENTS
TABLE 150. NOVALIQ GMBH: PRODUCT PORTFOLIO
TABLE 151. ALIMERA SCIENCES, INC.: KEY EXECUTIVES
TABLE 152. ALIMERA SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 153. ALIMERA SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 154. ALIMERA SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 155. NOCOX: KEY EXECUTIVES
TABLE 156. NOCOX: COMPANY SNAPSHOT
TABLE 157. NOCOX: PRODUCT SEGMENTS
TABLE 158. NOCOX: PRODUCT PORTFOLIO
TABLE 159. KIORA PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 160. KIORA PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 161. KIORA PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 162. KIORA PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. OCULAR DRUG DELIVERY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF OCULAR DRUG DELIVERY MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN OCULAR DRUG DELIVERY MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN OCULAR DRUG DELIVERY MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL OCULAR DRUG DELIVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR TOPICAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OCULAR INSERT, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR INTRAOCULAR IMPLANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR IN-SITU GEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR SOLUTION, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR EMULSION, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR SUSPENSION, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OINTMENT, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR DRY EYE SYNDROME, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR AGE RELATED MACULAR DEGENERATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. OCULAR DRUG DELIVERY MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OPHTHALMIC CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 32. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 33. OCULAR DRUG DELIVERY MARKET BY REGION, 2022 AND 2032(%)
FIGURE 34. U.S. OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 35. CANADA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 36. MEXICO OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 37. GERMANY OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 38. FRANCE OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 39. UK OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 40. ITALY OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 41. SPAIN OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 43. JAPAN OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 44. CHINA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 45. INDIA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 46. AUSTRALIA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 47. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 48. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 49. BRAZIL OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 50. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 51. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 52. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 53. TOP WINNING STRATEGIES, BY YEAR (2020-2021)
FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2021)
FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY (2020-2021)
FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 57. COMPETITIVE DASHBOARD
FIGURE 58. COMPETITIVE HEATMAP: OCULAR DRUG DELIVERY MARKET
FIGURE 59. TOP PLAYER POSITIONING, 2022
FIGURE 60. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. SANTEN PHARMACEUTICAL CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security